Objective To compare the efficacy and safety of follitropin delta, a new human recombinant FSH with individualized dosing based on serum antimüllerian hormone (AMH) and body weight, with conventional follitropin alfa dosing for ovarian stimulation in women undergoing IVF. Design Randomized, multicenter, assessor-blinded, noninferiority trial (ESTHER-1). Setting Reproductive medicine clinics. Patient(s) A total of 1,329 women (aged 18–40 years). Intervention(s) Follitropin delta (AMH <15 pmol/L: 12 μg/d; AMH ≥15 pmol/L: 0.10–0.19 μg/kg/d; maximum 12 μg/d), or follitropin alfa (150 IU/d for 5 days, potential subsequent dose adjustments; maximum 450 IU/d). Main Outcomes Measure(s) Ongoing pregnancy and ongoing implantation rates; noninferiority margins −8.0%. Result(s) Ongoing pregnancy (30.7% vs. 31.6%; difference −0.9% [95% confidence interval (CI) −5.9% to 4.1%]), ongoing implantation (35.2% vs. 35.8%; −0.6% [95% CI −6.1% to 4.8%]), and live birth (29.8% vs. 30.7%; −0.9% [95% CI −5.8% to 4.0%]) rates were similar for individualized follitropin delta and conventional follitropin alfa. Individualized follitropin delta resulted in more women with target response (8–14 oocytes) (43.3% vs. 38.4%), fewer poor responses (fewer than four oocytes in patients with AMH <15 pmol/L) (11.8% vs. 17.9%), fewer excessive responses (≥15 or ≥20 oocytes in patients with AMH ≥15 pmol/L) (27.9% vs. 35.1% and 10.1% vs. 15.6%, respectively), and fewer measures taken to prevent ovarian hyperstimulation syndrome (2.3% vs. 4.5%), despite similar oocyte yield (10.0 ± 5.6 vs. 10.4 ± 6.5) and similar blastocyst numbers (3.3 ± 2.8 vs. 3.5 ± 3.2), and less gonadotropin use (90.0 ± 25.3 vs. 103.7 ± 33.6 μg). Conclusion(s) Optimizing ovarian response in IVF by individualized dosing according to pretreatment patient characteristics results in similar efficacy and improved safety compared with conventional ovarian stimulation. Clinical Trial Registration Number NCT01956110.

Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial / Nyboe Andersen, Anders; Nelson, Scott M.; Fauser, Bart C. J. M.; García-Velasco, Juan Antonio; Klein, Bjarke M.; Arce, Joan-Carles; Tournaye, Herman; De Sutter, Petra; Decleer, Wim; Petracco, Alvaro; Borges, Edson; Barbosa, Caio Parente; Havelock, Jon; Claman, Paul; Yuzpe, Albert; Višnová, Hana; Ventruba, Pavel; Uher, Petr; Mrazek, Milan; Andersen, Anders Nyboe; Knudsen, Ulla Breth; Dewailly, Didier; Leveque, Anne Guivarc'h; La Marca, Antonio; Papaleo, Enrico; Kuczynski, Waldemar; Kozioł, Katarzyna; Anshina, Margarita; Zazerskaya, Irina; Gzgzyan, Alexander; Bulychova, Elena; Verdú, Victoria; Barri, Pedro; García-Velasco, Juan Antonio; Fernández-Sánchez, Manuel; Martin, Fernando Sánchez; Bosch, Ernesto; Serna, José; Castillon, Gemma; Bernabeu, Rafael; Ferrando, Marcos; Lavery, Stuart; Gaudoin, Marco; Fauser, Bart C. J. M.; Klein, Bjarke M.; Helmgaard, Lisbeth; Mannaerts, Bernadette; Arce, Joan-Carles. - In: FERTILITY AND STERILITY. - ISSN 0015-0282. - 107:2(2017), pp. 387-396.e4. [10.1016/j.fertnstert.2016.10.033]

Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial

La Marca, Antonio;
2017

Abstract

Objective To compare the efficacy and safety of follitropin delta, a new human recombinant FSH with individualized dosing based on serum antimüllerian hormone (AMH) and body weight, with conventional follitropin alfa dosing for ovarian stimulation in women undergoing IVF. Design Randomized, multicenter, assessor-blinded, noninferiority trial (ESTHER-1). Setting Reproductive medicine clinics. Patient(s) A total of 1,329 women (aged 18–40 years). Intervention(s) Follitropin delta (AMH <15 pmol/L: 12 μg/d; AMH ≥15 pmol/L: 0.10–0.19 μg/kg/d; maximum 12 μg/d), or follitropin alfa (150 IU/d for 5 days, potential subsequent dose adjustments; maximum 450 IU/d). Main Outcomes Measure(s) Ongoing pregnancy and ongoing implantation rates; noninferiority margins −8.0%. Result(s) Ongoing pregnancy (30.7% vs. 31.6%; difference −0.9% [95% confidence interval (CI) −5.9% to 4.1%]), ongoing implantation (35.2% vs. 35.8%; −0.6% [95% CI −6.1% to 4.8%]), and live birth (29.8% vs. 30.7%; −0.9% [95% CI −5.8% to 4.0%]) rates were similar for individualized follitropin delta and conventional follitropin alfa. Individualized follitropin delta resulted in more women with target response (8–14 oocytes) (43.3% vs. 38.4%), fewer poor responses (fewer than four oocytes in patients with AMH <15 pmol/L) (11.8% vs. 17.9%), fewer excessive responses (≥15 or ≥20 oocytes in patients with AMH ≥15 pmol/L) (27.9% vs. 35.1% and 10.1% vs. 15.6%, respectively), and fewer measures taken to prevent ovarian hyperstimulation syndrome (2.3% vs. 4.5%), despite similar oocyte yield (10.0 ± 5.6 vs. 10.4 ± 6.5) and similar blastocyst numbers (3.3 ± 2.8 vs. 3.5 ± 3.2), and less gonadotropin use (90.0 ± 25.3 vs. 103.7 ± 33.6 μg). Conclusion(s) Optimizing ovarian response in IVF by individualized dosing according to pretreatment patient characteristics results in similar efficacy and improved safety compared with conventional ovarian stimulation. Clinical Trial Registration Number NCT01956110.
2017
29-nov-2016
107
2
387
396.e4
Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial / Nyboe Andersen, Anders; Nelson, Scott M.; Fauser, Bart C. J. M.; García-Velasco, Juan Antonio; Klein, Bjarke M.; Arce, Joan-Carles; Tournaye, Herman; De Sutter, Petra; Decleer, Wim; Petracco, Alvaro; Borges, Edson; Barbosa, Caio Parente; Havelock, Jon; Claman, Paul; Yuzpe, Albert; Višnová, Hana; Ventruba, Pavel; Uher, Petr; Mrazek, Milan; Andersen, Anders Nyboe; Knudsen, Ulla Breth; Dewailly, Didier; Leveque, Anne Guivarc'h; La Marca, Antonio; Papaleo, Enrico; Kuczynski, Waldemar; Kozioł, Katarzyna; Anshina, Margarita; Zazerskaya, Irina; Gzgzyan, Alexander; Bulychova, Elena; Verdú, Victoria; Barri, Pedro; García-Velasco, Juan Antonio; Fernández-Sánchez, Manuel; Martin, Fernando Sánchez; Bosch, Ernesto; Serna, José; Castillon, Gemma; Bernabeu, Rafael; Ferrando, Marcos; Lavery, Stuart; Gaudoin, Marco; Fauser, Bart C. J. M.; Klein, Bjarke M.; Helmgaard, Lisbeth; Mannaerts, Bernadette; Arce, Joan-Carles. - In: FERTILITY AND STERILITY. - ISSN 0015-0282. - 107:2(2017), pp. 387-396.e4. [10.1016/j.fertnstert.2016.10.033]
Nyboe Andersen, Anders; Nelson, Scott M.; Fauser, Bart C. J. M.; García-Velasco, Juan Antonio; Klein, Bjarke M.; Arce, Joan-Carles; Tournaye, Herman; De Sutter, Petra; Decleer, Wim; Petracco, Alvaro; Borges, Edson; Barbosa, Caio Parente; Havelock, Jon; Claman, Paul; Yuzpe, Albert; Višnová, Hana; Ventruba, Pavel; Uher, Petr; Mrazek, Milan; Andersen, Anders Nyboe; Knudsen, Ulla Breth; Dewailly, Didier; Leveque, Anne Guivarc'h; La Marca, Antonio; Papaleo, Enrico; Kuczynski, Waldemar; Kozioł, Katarzyna; Anshina, Margarita; Zazerskaya, Irina; Gzgzyan, Alexander; Bulychova, Elena; Verdú, Victoria; Barri, Pedro; García-Velasco, Juan Antonio; Fernández-Sánchez, Manuel; Martin, Fernando Sánchez; Bosch, Ernesto; Serna, José; Castillon, Gemma; Bernabeu, Rafael; Ferrando, Marcos; Lavery, Stuart; Gaudoin, Marco; Fauser, Bart C. J. M.; Klein, Bjarke M.; Helmgaard, Lisbeth; Mannaerts, Bernadette; Arce, Joan-Carles
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0015028216629564-main.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 574.13 kB
Formato Adobe PDF
574.13 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1158571
Citazioni
  • ???jsp.display-item.citation.pmc??? 80
  • Scopus 189
  • ???jsp.display-item.citation.isi??? 160
social impact